Literature DB >> 12942572

Differential gene expression in leiomyosarcoma.

Keith M Skubitz1, Amy P N Skubitz.   

Abstract

BACKGROUND: Leiomyosarcomas (LMS) are a common subtype of soft tissue sarcoma. The molecular causes of the disease remain unclear.
METHODS: In the current study, gene expression in LMS, leiomyomas, and normal myometrium was examined. RNA was prepared and gene expression was determined using microarray analysis arrays containing approximately 12,000 known genes and 48,000 expressed sequence tags (ESTs).
RESULTS: A number of genes were found to be differentially expressed in these sample sets, and six genes including cyclin-dependent kinase inhibitor 2A, diaphanous (Drosophila homolog) 3, doublecortin, calpain 6, interleukin-17B, and proteolipid 1 were found to be overexpressed in LMS compared with normal myometrium and 18 other tissues. Sets of genes were identified whose expression could be used to cluster samples with either LMS, leiomyomas, or normal myometrium.
CONCLUSIONS: The authors concluded that differences in gene expression can be detected between LMS and leiomyomas, normal myometrium, and other tissues, and that these changes in gene expression may yield clues with regard to the pathophysiology of leiomyosarcoma. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 12942572     DOI: 10.1002/cncr.11586

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  36 in total

Review 1.  Role of gene expression arrays in sarcomas.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

Review 2.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

3.  Expression profiling of the cellular processes in uterine leiomyomas: omic approaches and IGF-2 association with leiomyosarcomas.

Authors:  Su Mi Bae; Yong-Wan Kim; Joon Mo Lee; Sung Eun Namkoong; Chong Kook Kim; Woong Shick Ahn
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

4.  The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

Authors:  Qing Zhang; Margaux Jenna Kanis; Julianne Ubago; Dachao Liu; Denise M Scholtens; Anna E Strohl; John R Lurain; Shohreh Shahabi; Beihua Kong; Jian-Jun Wei
Journal:  Hum Pathol       Date:  2017-12-16       Impact factor: 3.466

5.  Gene expression signatures of primary and metastatic uterine leiomyosarcoma.

Authors:  Ben Davidson; Vera Maria Abeler; Mette Førsund; Arild Holth; Yanqin Yang; Yusuke Kobayashi; Lily Chen; Gunnar B Kristensen; Ie-Ming Shih; Tian-Li Wang
Journal:  Hum Pathol       Date:  2013-11-13       Impact factor: 3.466

6.  Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient.

Authors:  Irina K Dimitrova; Jennifer K Richer; Michael C Rudolph; Nicole S Spoelstra; Elaine M Reno; Theresa M Medina; Andrew P Bradford
Journal:  Fertil Steril       Date:  2008-07-30       Impact factor: 7.329

7.  MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.

Authors:  Marcus Lehnhardt; Adrien Daigeler; Heinz H Homann; Vanessa Schwaiberger; Ole Goertz; Cornelius Kuhnen; Hans U Steinau
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

Review 8.  Malignant tumors of the uterine corpus: molecular background of their origin.

Authors:  D Brany; D Dvorska; M Nachajova; P Slavik; T Burjanivova
Journal:  Tumour Biol       Date:  2015-08-26

9.  Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Authors:  A H Beck; C-H Lee; D M Witten; B C Gleason; B Edris; I Espinosa; S Zhu; R Li; K D Montgomery; R J Marinelli; R Tibshirani; T Hastie; D M Jablons; B P Rubin; C D Fletcher; R B West; M van de Rijn
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

10.  Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin.

Authors:  A W Oosten; C Seynaeve; P I M Schmitz; M A den Bakker; J Verweij; S Sleijfer
Journal:  Sarcoma       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.